POSTERIOR SEGMENT DRUG DELIVERY
A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in th...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | Alster, Yair Chamow, Steven M George, Robert Sutton, Douglas Barrett, Michael de Juan, Jr., Eugene Farinas, Kathleen C Campbell, Randolph E Macfarlane, K. Angela Gifford, III, Hanson S Reich, Cary J |
| description | A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side.TABLE 1ATherapeutic Agent ListGeneric NameBrands (Companies)CategoryIndicationMolecular Weight2-Methoxyestradiol analogs(Paloma Pharmaceuticals)Angiogenesis inhibitorsAMD3-aminothalidomide13-cis retinoic acidAccutane™ (Roche Pharmaceuticals)A0003(Aqumen BioPharmaceuticals)A0003AMDA5b1 integrin inhibitor(Jerini Ophthalmic); (Ophthotech)Inhibitors of a5b1 integrinAMDAbarelixPlenaxis™(Praecis Pharmaceuticals)Anti-Testosterone Agents; Antineoplastic AgentsFor palliative treatment of advanced prostate cancer.37731AbataceptOrencia™(Bristol-Myers Squibb)Antirheumatic AgentsFor the second line reduction of the signs and symptoms of moderate-to-severe active rheumatoid arthritis, inducing inducing major clinical response, slowing the progression of structural damage, and improving physical function in adult patients who have37697AbciximabReoPro™; ReoPro™ (Centocor)Anticoagulants; Antiplatelet AgentsFor treatment of myocardial infarction, adjunct to percutaneous 2oronary intervention, unstable angina42632ABT-578(Abbott Laboratories)Limus Immunophilin Binding CompoundsAcetonideAdalimumabHumira™ (Abbott Laboratories)Antirheumatic Agents; Immunomodulatory AgentsFor treatment of rheumatoid arthritis25645AldesleukinProleukin™; Proleukin™ (Chiron Corp)Antineoplastic AgentsFor treatment of adults with metastatic renal cell carcinoma61118AlefaceptAmevive™Immunomodulatory Agents; Immunosuppressive AgentsFor treatment of moderate to severe chronic plaque psoriasis42632AlemtuzumabCampath™; Campath™ (ILEX Pharmaceuticals LP); MabCampath™Antineoplastic AgentsFor treatment of B-cell chronic lymphocytic leukemia6614Alpha-1-proteinase inhibitorAralast™ (Baxter); Prolastin™ (Talecris Biotherapeutics C formerly Bayer)Enzyme Replacement AgentsFor treatment of panacinar emphysema28518AlteplaseActivase™ (Genentech Inc)Thromboly |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US2023338282A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US2023338282A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US2023338282A13</originalsourceid><addsrcrecordid>eNrjZJAP8A8OcQ3y9A9SCHZ193X1C1FwCQp1V3Bx9fEMcw2K5GFgTUvMKU7lhdLcDMpuriHOHrqpBfnxqcUFicmpeakl8aHBRgZGxsbGFkYWRo6GxsSpAgB1CyLM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>POSTERIOR SEGMENT DRUG DELIVERY</title><source>esp@cenet</source><creator>Alster, Yair ; Chamow, Steven M ; George, Robert ; Sutton, Douglas ; Barrett, Michael ; de Juan, Jr., Eugene ; Farinas, Kathleen C ; Campbell, Randolph E ; Macfarlane, K. Angela ; Gifford, III, Hanson S ; Reich, Cary J</creator><creatorcontrib>Alster, Yair ; Chamow, Steven M ; George, Robert ; Sutton, Douglas ; Barrett, Michael ; de Juan, Jr., Eugene ; Farinas, Kathleen C ; Campbell, Randolph E ; Macfarlane, K. Angela ; Gifford, III, Hanson S ; Reich, Cary J</creatorcontrib><description>A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side.TABLE 1ATherapeutic Agent ListGeneric NameBrands (Companies)CategoryIndicationMolecular Weight2-Methoxyestradiol analogs(Paloma Pharmaceuticals)Angiogenesis inhibitorsAMD3-aminothalidomide13-cis retinoic acidAccutane™ (Roche Pharmaceuticals)A0003(Aqumen BioPharmaceuticals)A0003AMDA5b1 integrin inhibitor(Jerini Ophthalmic); (Ophthotech)Inhibitors of a5b1 integrinAMDAbarelixPlenaxis™(Praecis Pharmaceuticals)Anti-Testosterone Agents; Antineoplastic AgentsFor palliative treatment of advanced prostate cancer.37731AbataceptOrencia™(Bristol-Myers Squibb)Antirheumatic AgentsFor the second line reduction of the signs and symptoms of moderate-to-severe active rheumatoid arthritis, inducing inducing major clinical response, slowing the progression of structural damage, and improving physical function in adult patients who have37697AbciximabReoPro™; ReoPro™ (Centocor)Anticoagulants; Antiplatelet AgentsFor treatment of myocardial infarction, adjunct to percutaneous 2oronary intervention, unstable angina42632ABT-578(Abbott Laboratories)Limus Immunophilin Binding CompoundsAcetonideAdalimumabHumira™ (Abbott Laboratories)Antirheumatic Agents; Immunomodulatory AgentsFor treatment of rheumatoid arthritis25645AldesleukinProleukin™; Proleukin™ (Chiron Corp)Antineoplastic AgentsFor treatment of adults with metastatic renal cell carcinoma61118AlefaceptAmevive™Immunomodulatory Agents; Immunosuppressive AgentsFor treatment of moderate to severe chronic plaque psoriasis42632AlemtuzumabCampath™; Campath™ (ILEX Pharmaceuticals LP); MabCampath™Antineoplastic AgentsFor treatment of B-cell chronic lymphocytic leukemia6614Alpha-1-proteinase inhibitorAralast™ (Baxter); Prolastin™ (Talecris Biotherapeutics C formerly Bayer)Enzyme Replacement AgentsFor treatment of panacinar emphysema28518AlteplaseActivase™ (Genentech Inc)Thrombolytic AgentsFor management of acute myocardial infarction, acute ischemic strok and for lysis of acute pulmonary emboli54732AMG-1470AnakinraKineret™ (Amgen Inc)Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Immunomodulatory AgentsFor the treatment of adult rheumatoid arthritis.65403Anecortave acetateAngiostatinAnistreplaseEminase™ (Wulfing Pharma GmbH)Thrombolytic AgentsFor lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction54732Anti-angiogenesis peptides(Eyecopharm)Anti-angiogenesis peptidesAMDAnti-angiogenesis antibodies, TRC093, TRC105(TRACON Pharma)Anti-angiogenesis antibodiesAMDAnti-angiogeric bifunctional proteinIcon-1™ (Iconic Therapeutics)Anti-angiogeric bifunctional protein, Icon-1AMDAnti-endothelial growth factorAntihemophilic FactorAdvate™; Alphanate™; Bioclate™; Helixate™; Helixate FS™; Hemofil M™; Humate-P™;Coagulants; Thrombotic AgentsFor the treatment of hemophilia A, von Willebrand diseae and Factor XIII deficiency70037Hyate:C™; Koate-HP™; Kogenate™; Kogenate FS™; Monarc-M™; Monoclate-P™; ReFacto™; Xyntha™Antithymocyte globulinGenzyme); Thymoglobulin™ (SangStat MedicalImmunomodulatory AgentsFor prevention of renal transplant rejection37173Anti-hypertensive MC1101(MacuCLEAR)Anti-hypertensive MC1101AMDAnti-platelet devired growth factorAnti-VEGF(Neurotech); Avastin™ (NeoVista)Anti-VEGFAMDAP23841(Ariad)Limus Immunophilin Binding CompoundsAprotininTrasylol™Antifibrinolytic AgentsFor prophylactic use to reduce perioperative blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass in the course of coronary artery bypass graft surgery who are at an increased risk for blood loss and blood transfusio90569ArcitumomabCEA-Scan™Diagnostic Agents; Imaging AgentsFor imaging colorectal tumors57561AsparaginaseElspar™ (Merck & Co. Inc)Antineoplastic AgentsFor treatment of acute lympocytic leukemia and non-Hodgkins lymphoma132.118AxitinibTyrosine Kinase Inhibitors386BasiliximabSimulect™ (Novartis Pharmaceuticals)Immunomodulatory Agents; Immunosuppressive AgentsFor prophylactic treatment of kidney transplant rejection61118BecaplerminRegranex™; Regranex™ (OMJ Pharmaceuticals)Anti-Ulcer Agents; TopicalFor topical treatment of skin ulcers (from diabetes)123969BevacizumabAvastin™; Avastin™ (Genentech Inc)Antiangiogenesis Agents; Antineoplastic AgentsFor treatment of metastatic colorectal cancer27043BivalirudinAngiomax™; Angiomax™ (Medicines Co or MDCO); Angiox™Anticoagulants; Antithrombotic AgentsFor treatment of heparin-induced thrombocytopenia70037BortezomibProteosome InhibitorsBosutinibTyrosine Kinase Inhibitors530Botulinum Toxin Type ABOTOX™(Allegran Inc); BOTOX Cosmetic™ (Allegran Inc); Botox™; Dysport™Anti-Wrinkle Agents; Antidystonic Agents; Neuromuscular Blocking AgentsFor the treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia. Also for the treatment of severe primary axillary hyperhidrosis that is inadequately managed with topical23315Botulinum Toxin Type BMyobloc™ (Solstice Neurosciences); Neurobloc™ (Solstice Neurosciences)Antidystonic AgentsFor the treatment of patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia.12902C5 inhibitor(Jerini Ophthalmic) ; (Ophthotech)Inhibitors of C5AMDCanstatinCapromabProstaScint™ (Cytogen Corp)Imaging AgentsFor diagnosis of prostate cancer and detection of intra-pelvic metastases84331CaptoprilACE InhibitorsCCI-779(Wyeth)Limus Immunophilin Binding CompoundsCediranibTyrosine Kinase Inhibitors450CelecoxibCyclooxygenase InhibitorsCetrorelixCetrotide™Hormone Antagonists; Infertility AgentsFor the inhibition of premature LH surges in women undergoing controlled ovarian stimulation78617CetuximabErbitux™; Erbitux™ (ImClone Systems Inc)Antineoplastic AgentsFor treatment of metastatic colorectal cancer.42632Choriogonadotropin alfaNovarel™; Ovidrel™; Pregnyl™; Profasi™Fertility Agents; GonadotropinsFor the treatment of female infertility78617Cilary neurotrophic factor(Neurotech)Cilary neurotrophic factorAMDCoagulation Factor IXBenefix™ (Genetics Institute)Coagulants; Thrombotic AgentsFor treatment of hemophilia (Christmas disease).267012Coagulation factor VIIaNovoSeven™ (Novo Nordisk)Coagulants; Thrombotic AgentsFor treatment of hemorrhagic complications in hemophilia A and B54732ColchicinesCollagenaseCordase™; Santyl™ (Advance Biofactures Corp); Xiaflextm™Anti-Ulcer Agents; TopicalFor treatment of chronic dermal ulcers and severe skin burns138885Complement factor H recombinant(Optherion); (Taligen Therapeutics)Complement factor H recombinantAMDCompstatin derivative peptide, POT-4(Potentia Pharmaceuticals)Complement Factor C3 Inhibitors; Compstatin Derivative PeptidesAMDCorticotropinACTH™; Acethropan™; Acortan™; Acthar™; Exacthin™; H.P. Acthar Gel™; Isactid™; Purified cortrophin gel™; Reacthin™; Solacthyl™; TubexDiagnostic AgentsFor use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency.33927CosyntropinCortrosyn™; Synacthen depot™Diagnostic AgentsFor use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency.33927CyclophilinsLimus Immunophilin Binding CompoundsCyclosporineGengraf™ (Abbott labs); Neoral™ (Novartis); Restasis™; Restasis™ (Allergan Inc); Sandimmune™ (Novartis); Sangcya™Antifungal Agents; Antirheumatic Agents; Dermatologic Agents; Enzyme Inhibitors; Immunomodulatory Agents; Immunosuppressive AgentsFor treatment of transplant rejection, rheumatoid arthritis, severe psoriasis32953DaclizumabZenapax™ (Hoffmann-La Roche Inc)Immunomodulatory Agents; Immunosuppressive AgentsFor prevention of renal transplant rejection61118Darbepoetin alfaAranesp™ (Amgen Inc.)Antianemic AgentsFor the treatment of anemia (from renal transplants or certain HIV treatment)55066DasatinibTyrosine Kinase Inhibitors488DefibrotideDasovas™; Noravid™; Prociclide™Antithrombotic AgentsDefibrotide is used to treat or prevent a failure of normal blood flow (occlusive venous disease, OVD) in the liver of patients who have had bone marrow transplants or received certain drugs such as oral estrogens, mercaptopurine, and many others.36512Denileukin diftitoxOntak™Antineoplastic AgentsFor treatment of cutaneous T-cell lymphoma61118DesmopressinAdiuretin™; Concentraid™; Stimate™Antidiuretic Agents; Hemostatics; Renal AgentsFor the management of primary nocturnal enuresis and indicated as antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pitu46800DexamethasoneOzurdex™ (Allergan)GlucocorticoidDME, inflammation, macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO)392DiclofenacCyclooxygenase InhibitorsDithiocarbamateNFκB InhibitorDornase AlfaDilor™; Dilor-400™; Lufyllin™; Lufyllin-400™; Neothylline™; Pulmozyme™ (Genentech Inc)Enzyme Replacement AgentsFor the treatment of cystic fibrosis.7656 (double strand)Drotrecogin alfaXigris™; Xigris™ (Eli Lilly & Co)Antisepsis AgentsFor treatment of severe sepsis267012EculizumabSoliris™; Soliris™ (Alexion Pharmaceuticals)For the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.188333EfalizumabRaptiva™; Raptiva™ (Genentech Inc)Immunomodulatory Agents; Immunosuppressive AgentsFo</description><language>eng</language><subject>BANDAGES, DRESSINGS OR ABSORBENT PADS ; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF,TUBULAR STRUCTURES OF THE BODY, E.G. STENTS ; FILTERS IMPLANTABLE INTO BLOOD VESSELS ; FIRST-AID KITS ; FOMENTATION ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROSTHESES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; TREATMENT OR PROTECTION OF EYES OR EARS</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20231026&DB=EPODOC&CC=US&NR=2023338282A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76290</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20231026&DB=EPODOC&CC=US&NR=2023338282A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Alster, Yair</creatorcontrib><creatorcontrib>Chamow, Steven M</creatorcontrib><creatorcontrib>George, Robert</creatorcontrib><creatorcontrib>Sutton, Douglas</creatorcontrib><creatorcontrib>Barrett, Michael</creatorcontrib><creatorcontrib>de Juan, Jr., Eugene</creatorcontrib><creatorcontrib>Farinas, Kathleen C</creatorcontrib><creatorcontrib>Campbell, Randolph E</creatorcontrib><creatorcontrib>Macfarlane, K. Angela</creatorcontrib><creatorcontrib>Gifford, III, Hanson S</creatorcontrib><creatorcontrib>Reich, Cary J</creatorcontrib><title>POSTERIOR SEGMENT DRUG DELIVERY</title><description>A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side.TABLE 1ATherapeutic Agent ListGeneric NameBrands (Companies)CategoryIndicationMolecular Weight2-Methoxyestradiol analogs(Paloma Pharmaceuticals)Angiogenesis inhibitorsAMD3-aminothalidomide13-cis retinoic acidAccutane™ (Roche Pharmaceuticals)A0003(Aqumen BioPharmaceuticals)A0003AMDA5b1 integrin inhibitor(Jerini Ophthalmic); (Ophthotech)Inhibitors of a5b1 integrinAMDAbarelixPlenaxis™(Praecis Pharmaceuticals)Anti-Testosterone Agents; Antineoplastic AgentsFor palliative treatment of advanced prostate cancer.37731AbataceptOrencia™(Bristol-Myers Squibb)Antirheumatic AgentsFor the second line reduction of the signs and symptoms of moderate-to-severe active rheumatoid arthritis, inducing inducing major clinical response, slowing the progression of structural damage, and improving physical function in adult patients who have37697AbciximabReoPro™; ReoPro™ (Centocor)Anticoagulants; Antiplatelet AgentsFor treatment of myocardial infarction, adjunct to percutaneous 2oronary intervention, unstable angina42632ABT-578(Abbott Laboratories)Limus Immunophilin Binding CompoundsAcetonideAdalimumabHumira™ (Abbott Laboratories)Antirheumatic Agents; Immunomodulatory AgentsFor treatment of rheumatoid arthritis25645AldesleukinProleukin™; Proleukin™ (Chiron Corp)Antineoplastic AgentsFor treatment of adults with metastatic renal cell carcinoma61118AlefaceptAmevive™Immunomodulatory Agents; Immunosuppressive AgentsFor treatment of moderate to severe chronic plaque psoriasis42632AlemtuzumabCampath™; Campath™ (ILEX Pharmaceuticals LP); MabCampath™Antineoplastic AgentsFor treatment of B-cell chronic lymphocytic leukemia6614Alpha-1-proteinase inhibitorAralast™ (Baxter); Prolastin™ (Talecris Biotherapeutics C formerly Bayer)Enzyme Replacement AgentsFor treatment of panacinar emphysema28518AlteplaseActivase™ (Genentech Inc)Thrombolytic AgentsFor management of acute myocardial infarction, acute ischemic strok and for lysis of acute pulmonary emboli54732AMG-1470AnakinraKineret™ (Amgen Inc)Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Immunomodulatory AgentsFor the treatment of adult rheumatoid arthritis.65403Anecortave acetateAngiostatinAnistreplaseEminase™ (Wulfing Pharma GmbH)Thrombolytic AgentsFor lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction54732Anti-angiogenesis peptides(Eyecopharm)Anti-angiogenesis peptidesAMDAnti-angiogenesis antibodies, TRC093, TRC105(TRACON Pharma)Anti-angiogenesis antibodiesAMDAnti-angiogeric bifunctional proteinIcon-1™ (Iconic Therapeutics)Anti-angiogeric bifunctional protein, Icon-1AMDAnti-endothelial growth factorAntihemophilic FactorAdvate™; Alphanate™; Bioclate™; Helixate™; Helixate FS™; Hemofil M™; Humate-P™;Coagulants; Thrombotic AgentsFor the treatment of hemophilia A, von Willebrand diseae and Factor XIII deficiency70037Hyate:C™; Koate-HP™; Kogenate™; Kogenate FS™; Monarc-M™; Monoclate-P™; ReFacto™; Xyntha™Antithymocyte globulinGenzyme); Thymoglobulin™ (SangStat MedicalImmunomodulatory AgentsFor prevention of renal transplant rejection37173Anti-hypertensive MC1101(MacuCLEAR)Anti-hypertensive MC1101AMDAnti-platelet devired growth factorAnti-VEGF(Neurotech); Avastin™ (NeoVista)Anti-VEGFAMDAP23841(Ariad)Limus Immunophilin Binding CompoundsAprotininTrasylol™Antifibrinolytic AgentsFor prophylactic use to reduce perioperative blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass in the course of coronary artery bypass graft surgery who are at an increased risk for blood loss and blood transfusio90569ArcitumomabCEA-Scan™Diagnostic Agents; Imaging AgentsFor imaging colorectal tumors57561AsparaginaseElspar™ (Merck & Co. Inc)Antineoplastic AgentsFor treatment of acute lympocytic leukemia and non-Hodgkins lymphoma132.118AxitinibTyrosine Kinase Inhibitors386BasiliximabSimulect™ (Novartis Pharmaceuticals)Immunomodulatory Agents; Immunosuppressive AgentsFor prophylactic treatment of kidney transplant rejection61118BecaplerminRegranex™; Regranex™ (OMJ Pharmaceuticals)Anti-Ulcer Agents; TopicalFor topical treatment of skin ulcers (from diabetes)123969BevacizumabAvastin™; Avastin™ (Genentech Inc)Antiangiogenesis Agents; Antineoplastic AgentsFor treatment of metastatic colorectal cancer27043BivalirudinAngiomax™; Angiomax™ (Medicines Co or MDCO); Angiox™Anticoagulants; Antithrombotic AgentsFor treatment of heparin-induced thrombocytopenia70037BortezomibProteosome InhibitorsBosutinibTyrosine Kinase Inhibitors530Botulinum Toxin Type ABOTOX™(Allegran Inc); BOTOX Cosmetic™ (Allegran Inc); Botox™; Dysport™Anti-Wrinkle Agents; Antidystonic Agents; Neuromuscular Blocking AgentsFor the treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia. Also for the treatment of severe primary axillary hyperhidrosis that is inadequately managed with topical23315Botulinum Toxin Type BMyobloc™ (Solstice Neurosciences); Neurobloc™ (Solstice Neurosciences)Antidystonic AgentsFor the treatment of patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia.12902C5 inhibitor(Jerini Ophthalmic) ; (Ophthotech)Inhibitors of C5AMDCanstatinCapromabProstaScint™ (Cytogen Corp)Imaging AgentsFor diagnosis of prostate cancer and detection of intra-pelvic metastases84331CaptoprilACE InhibitorsCCI-779(Wyeth)Limus Immunophilin Binding CompoundsCediranibTyrosine Kinase Inhibitors450CelecoxibCyclooxygenase InhibitorsCetrorelixCetrotide™Hormone Antagonists; Infertility AgentsFor the inhibition of premature LH surges in women undergoing controlled ovarian stimulation78617CetuximabErbitux™; Erbitux™ (ImClone Systems Inc)Antineoplastic AgentsFor treatment of metastatic colorectal cancer.42632Choriogonadotropin alfaNovarel™; Ovidrel™; Pregnyl™; Profasi™Fertility Agents; GonadotropinsFor the treatment of female infertility78617Cilary neurotrophic factor(Neurotech)Cilary neurotrophic factorAMDCoagulation Factor IXBenefix™ (Genetics Institute)Coagulants; Thrombotic AgentsFor treatment of hemophilia (Christmas disease).267012Coagulation factor VIIaNovoSeven™ (Novo Nordisk)Coagulants; Thrombotic AgentsFor treatment of hemorrhagic complications in hemophilia A and B54732ColchicinesCollagenaseCordase™; Santyl™ (Advance Biofactures Corp); Xiaflextm™Anti-Ulcer Agents; TopicalFor treatment of chronic dermal ulcers and severe skin burns138885Complement factor H recombinant(Optherion); (Taligen Therapeutics)Complement factor H recombinantAMDCompstatin derivative peptide, POT-4(Potentia Pharmaceuticals)Complement Factor C3 Inhibitors; Compstatin Derivative PeptidesAMDCorticotropinACTH™; Acethropan™; Acortan™; Acthar™; Exacthin™; H.P. Acthar Gel™; Isactid™; Purified cortrophin gel™; Reacthin™; Solacthyl™; TubexDiagnostic AgentsFor use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency.33927CosyntropinCortrosyn™; Synacthen depot™Diagnostic AgentsFor use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency.33927CyclophilinsLimus Immunophilin Binding CompoundsCyclosporineGengraf™ (Abbott labs); Neoral™ (Novartis); Restasis™; Restasis™ (Allergan Inc); Sandimmune™ (Novartis); Sangcya™Antifungal Agents; Antirheumatic Agents; Dermatologic Agents; Enzyme Inhibitors; Immunomodulatory Agents; Immunosuppressive AgentsFor treatment of transplant rejection, rheumatoid arthritis, severe psoriasis32953DaclizumabZenapax™ (Hoffmann-La Roche Inc)Immunomodulatory Agents; Immunosuppressive AgentsFor prevention of renal transplant rejection61118Darbepoetin alfaAranesp™ (Amgen Inc.)Antianemic AgentsFor the treatment of anemia (from renal transplants or certain HIV treatment)55066DasatinibTyrosine Kinase Inhibitors488DefibrotideDasovas™; Noravid™; Prociclide™Antithrombotic AgentsDefibrotide is used to treat or prevent a failure of normal blood flow (occlusive venous disease, OVD) in the liver of patients who have had bone marrow transplants or received certain drugs such as oral estrogens, mercaptopurine, and many others.36512Denileukin diftitoxOntak™Antineoplastic AgentsFor treatment of cutaneous T-cell lymphoma61118DesmopressinAdiuretin™; Concentraid™; Stimate™Antidiuretic Agents; Hemostatics; Renal AgentsFor the management of primary nocturnal enuresis and indicated as antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pitu46800DexamethasoneOzurdex™ (Allergan)GlucocorticoidDME, inflammation, macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO)392DiclofenacCyclooxygenase InhibitorsDithiocarbamateNFκB InhibitorDornase AlfaDilor™; Dilor-400™; Lufyllin™; Lufyllin-400™; Neothylline™; Pulmozyme™ (Genentech Inc)Enzyme Replacement AgentsFor the treatment of cystic fibrosis.7656 (double strand)Drotrecogin alfaXigris™; Xigris™ (Eli Lilly & Co)Antisepsis AgentsFor treatment of severe sepsis267012EculizumabSoliris™; Soliris™ (Alexion Pharmaceuticals)For the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.188333EfalizumabRaptiva™; Raptiva™ (Genentech Inc)Immunomodulatory Agents; Immunosuppressive AgentsFo</description><subject>BANDAGES, DRESSINGS OR ABSORBENT PADS</subject><subject>DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF,TUBULAR STRUCTURES OF THE BODY, E.G. STENTS</subject><subject>FILTERS IMPLANTABLE INTO BLOOD VESSELS</subject><subject>FIRST-AID KITS</subject><subject>FOMENTATION</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROSTHESES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>TREATMENT OR PROTECTION OF EYES OR EARS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZJAP8A8OcQ3y9A9SCHZ193X1C1FwCQp1V3Bx9fEMcw2K5GFgTUvMKU7lhdLcDMpuriHOHrqpBfnxqcUFicmpeakl8aHBRgZGxsbGFkYWRo6GxsSpAgB1CyLM</recordid><startdate>20231026</startdate><enddate>20231026</enddate><creator>Alster, Yair</creator><creator>Chamow, Steven M</creator><creator>George, Robert</creator><creator>Sutton, Douglas</creator><creator>Barrett, Michael</creator><creator>de Juan, Jr., Eugene</creator><creator>Farinas, Kathleen C</creator><creator>Campbell, Randolph E</creator><creator>Macfarlane, K. Angela</creator><creator>Gifford, III, Hanson S</creator><creator>Reich, Cary J</creator><scope>EVB</scope></search><sort><creationdate>20231026</creationdate><title>POSTERIOR SEGMENT DRUG DELIVERY</title><author>Alster, Yair ; Chamow, Steven M ; George, Robert ; Sutton, Douglas ; Barrett, Michael ; de Juan, Jr., Eugene ; Farinas, Kathleen C ; Campbell, Randolph E ; Macfarlane, K. Angela ; Gifford, III, Hanson S ; Reich, Cary J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US2023338282A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2023</creationdate><topic>BANDAGES, DRESSINGS OR ABSORBENT PADS</topic><topic>DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF,TUBULAR STRUCTURES OF THE BODY, E.G. STENTS</topic><topic>FILTERS IMPLANTABLE INTO BLOOD VESSELS</topic><topic>FIRST-AID KITS</topic><topic>FOMENTATION</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROSTHESES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>TREATMENT OR PROTECTION OF EYES OR EARS</topic><toplevel>online_resources</toplevel><creatorcontrib>Alster, Yair</creatorcontrib><creatorcontrib>Chamow, Steven M</creatorcontrib><creatorcontrib>George, Robert</creatorcontrib><creatorcontrib>Sutton, Douglas</creatorcontrib><creatorcontrib>Barrett, Michael</creatorcontrib><creatorcontrib>de Juan, Jr., Eugene</creatorcontrib><creatorcontrib>Farinas, Kathleen C</creatorcontrib><creatorcontrib>Campbell, Randolph E</creatorcontrib><creatorcontrib>Macfarlane, K. Angela</creatorcontrib><creatorcontrib>Gifford, III, Hanson S</creatorcontrib><creatorcontrib>Reich, Cary J</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Alster, Yair</au><au>Chamow, Steven M</au><au>George, Robert</au><au>Sutton, Douglas</au><au>Barrett, Michael</au><au>de Juan, Jr., Eugene</au><au>Farinas, Kathleen C</au><au>Campbell, Randolph E</au><au>Macfarlane, K. Angela</au><au>Gifford, III, Hanson S</au><au>Reich, Cary J</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>POSTERIOR SEGMENT DRUG DELIVERY</title><date>2023-10-26</date><risdate>2023</risdate><abstract>A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side.TABLE 1ATherapeutic Agent ListGeneric NameBrands (Companies)CategoryIndicationMolecular Weight2-Methoxyestradiol analogs(Paloma Pharmaceuticals)Angiogenesis inhibitorsAMD3-aminothalidomide13-cis retinoic acidAccutane™ (Roche Pharmaceuticals)A0003(Aqumen BioPharmaceuticals)A0003AMDA5b1 integrin inhibitor(Jerini Ophthalmic); (Ophthotech)Inhibitors of a5b1 integrinAMDAbarelixPlenaxis™(Praecis Pharmaceuticals)Anti-Testosterone Agents; Antineoplastic AgentsFor palliative treatment of advanced prostate cancer.37731AbataceptOrencia™(Bristol-Myers Squibb)Antirheumatic AgentsFor the second line reduction of the signs and symptoms of moderate-to-severe active rheumatoid arthritis, inducing inducing major clinical response, slowing the progression of structural damage, and improving physical function in adult patients who have37697AbciximabReoPro™; ReoPro™ (Centocor)Anticoagulants; Antiplatelet AgentsFor treatment of myocardial infarction, adjunct to percutaneous 2oronary intervention, unstable angina42632ABT-578(Abbott Laboratories)Limus Immunophilin Binding CompoundsAcetonideAdalimumabHumira™ (Abbott Laboratories)Antirheumatic Agents; Immunomodulatory AgentsFor treatment of rheumatoid arthritis25645AldesleukinProleukin™; Proleukin™ (Chiron Corp)Antineoplastic AgentsFor treatment of adults with metastatic renal cell carcinoma61118AlefaceptAmevive™Immunomodulatory Agents; Immunosuppressive AgentsFor treatment of moderate to severe chronic plaque psoriasis42632AlemtuzumabCampath™; Campath™ (ILEX Pharmaceuticals LP); MabCampath™Antineoplastic AgentsFor treatment of B-cell chronic lymphocytic leukemia6614Alpha-1-proteinase inhibitorAralast™ (Baxter); Prolastin™ (Talecris Biotherapeutics C formerly Bayer)Enzyme Replacement AgentsFor treatment of panacinar emphysema28518AlteplaseActivase™ (Genentech Inc)Thrombolytic AgentsFor management of acute myocardial infarction, acute ischemic strok and for lysis of acute pulmonary emboli54732AMG-1470AnakinraKineret™ (Amgen Inc)Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Immunomodulatory AgentsFor the treatment of adult rheumatoid arthritis.65403Anecortave acetateAngiostatinAnistreplaseEminase™ (Wulfing Pharma GmbH)Thrombolytic AgentsFor lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction54732Anti-angiogenesis peptides(Eyecopharm)Anti-angiogenesis peptidesAMDAnti-angiogenesis antibodies, TRC093, TRC105(TRACON Pharma)Anti-angiogenesis antibodiesAMDAnti-angiogeric bifunctional proteinIcon-1™ (Iconic Therapeutics)Anti-angiogeric bifunctional protein, Icon-1AMDAnti-endothelial growth factorAntihemophilic FactorAdvate™; Alphanate™; Bioclate™; Helixate™; Helixate FS™; Hemofil M™; Humate-P™;Coagulants; Thrombotic AgentsFor the treatment of hemophilia A, von Willebrand diseae and Factor XIII deficiency70037Hyate:C™; Koate-HP™; Kogenate™; Kogenate FS™; Monarc-M™; Monoclate-P™; ReFacto™; Xyntha™Antithymocyte globulinGenzyme); Thymoglobulin™ (SangStat MedicalImmunomodulatory AgentsFor prevention of renal transplant rejection37173Anti-hypertensive MC1101(MacuCLEAR)Anti-hypertensive MC1101AMDAnti-platelet devired growth factorAnti-VEGF(Neurotech); Avastin™ (NeoVista)Anti-VEGFAMDAP23841(Ariad)Limus Immunophilin Binding CompoundsAprotininTrasylol™Antifibrinolytic AgentsFor prophylactic use to reduce perioperative blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass in the course of coronary artery bypass graft surgery who are at an increased risk for blood loss and blood transfusio90569ArcitumomabCEA-Scan™Diagnostic Agents; Imaging AgentsFor imaging colorectal tumors57561AsparaginaseElspar™ (Merck & Co. Inc)Antineoplastic AgentsFor treatment of acute lympocytic leukemia and non-Hodgkins lymphoma132.118AxitinibTyrosine Kinase Inhibitors386BasiliximabSimulect™ (Novartis Pharmaceuticals)Immunomodulatory Agents; Immunosuppressive AgentsFor prophylactic treatment of kidney transplant rejection61118BecaplerminRegranex™; Regranex™ (OMJ Pharmaceuticals)Anti-Ulcer Agents; TopicalFor topical treatment of skin ulcers (from diabetes)123969BevacizumabAvastin™; Avastin™ (Genentech Inc)Antiangiogenesis Agents; Antineoplastic AgentsFor treatment of metastatic colorectal cancer27043BivalirudinAngiomax™; Angiomax™ (Medicines Co or MDCO); Angiox™Anticoagulants; Antithrombotic AgentsFor treatment of heparin-induced thrombocytopenia70037BortezomibProteosome InhibitorsBosutinibTyrosine Kinase Inhibitors530Botulinum Toxin Type ABOTOX™(Allegran Inc); BOTOX Cosmetic™ (Allegran Inc); Botox™; Dysport™Anti-Wrinkle Agents; Antidystonic Agents; Neuromuscular Blocking AgentsFor the treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia. Also for the treatment of severe primary axillary hyperhidrosis that is inadequately managed with topical23315Botulinum Toxin Type BMyobloc™ (Solstice Neurosciences); Neurobloc™ (Solstice Neurosciences)Antidystonic AgentsFor the treatment of patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia.12902C5 inhibitor(Jerini Ophthalmic) ; (Ophthotech)Inhibitors of C5AMDCanstatinCapromabProstaScint™ (Cytogen Corp)Imaging AgentsFor diagnosis of prostate cancer and detection of intra-pelvic metastases84331CaptoprilACE InhibitorsCCI-779(Wyeth)Limus Immunophilin Binding CompoundsCediranibTyrosine Kinase Inhibitors450CelecoxibCyclooxygenase InhibitorsCetrorelixCetrotide™Hormone Antagonists; Infertility AgentsFor the inhibition of premature LH surges in women undergoing controlled ovarian stimulation78617CetuximabErbitux™; Erbitux™ (ImClone Systems Inc)Antineoplastic AgentsFor treatment of metastatic colorectal cancer.42632Choriogonadotropin alfaNovarel™; Ovidrel™; Pregnyl™; Profasi™Fertility Agents; GonadotropinsFor the treatment of female infertility78617Cilary neurotrophic factor(Neurotech)Cilary neurotrophic factorAMDCoagulation Factor IXBenefix™ (Genetics Institute)Coagulants; Thrombotic AgentsFor treatment of hemophilia (Christmas disease).267012Coagulation factor VIIaNovoSeven™ (Novo Nordisk)Coagulants; Thrombotic AgentsFor treatment of hemorrhagic complications in hemophilia A and B54732ColchicinesCollagenaseCordase™; Santyl™ (Advance Biofactures Corp); Xiaflextm™Anti-Ulcer Agents; TopicalFor treatment of chronic dermal ulcers and severe skin burns138885Complement factor H recombinant(Optherion); (Taligen Therapeutics)Complement factor H recombinantAMDCompstatin derivative peptide, POT-4(Potentia Pharmaceuticals)Complement Factor C3 Inhibitors; Compstatin Derivative PeptidesAMDCorticotropinACTH™; Acethropan™; Acortan™; Acthar™; Exacthin™; H.P. Acthar Gel™; Isactid™; Purified cortrophin gel™; Reacthin™; Solacthyl™; TubexDiagnostic AgentsFor use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency.33927CosyntropinCortrosyn™; Synacthen depot™Diagnostic AgentsFor use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency.33927CyclophilinsLimus Immunophilin Binding CompoundsCyclosporineGengraf™ (Abbott labs); Neoral™ (Novartis); Restasis™; Restasis™ (Allergan Inc); Sandimmune™ (Novartis); Sangcya™Antifungal Agents; Antirheumatic Agents; Dermatologic Agents; Enzyme Inhibitors; Immunomodulatory Agents; Immunosuppressive AgentsFor treatment of transplant rejection, rheumatoid arthritis, severe psoriasis32953DaclizumabZenapax™ (Hoffmann-La Roche Inc)Immunomodulatory Agents; Immunosuppressive AgentsFor prevention of renal transplant rejection61118Darbepoetin alfaAranesp™ (Amgen Inc.)Antianemic AgentsFor the treatment of anemia (from renal transplants or certain HIV treatment)55066DasatinibTyrosine Kinase Inhibitors488DefibrotideDasovas™; Noravid™; Prociclide™Antithrombotic AgentsDefibrotide is used to treat or prevent a failure of normal blood flow (occlusive venous disease, OVD) in the liver of patients who have had bone marrow transplants or received certain drugs such as oral estrogens, mercaptopurine, and many others.36512Denileukin diftitoxOntak™Antineoplastic AgentsFor treatment of cutaneous T-cell lymphoma61118DesmopressinAdiuretin™; Concentraid™; Stimate™Antidiuretic Agents; Hemostatics; Renal AgentsFor the management of primary nocturnal enuresis and indicated as antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pitu46800DexamethasoneOzurdex™ (Allergan)GlucocorticoidDME, inflammation, macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO)392DiclofenacCyclooxygenase InhibitorsDithiocarbamateNFκB InhibitorDornase AlfaDilor™; Dilor-400™; Lufyllin™; Lufyllin-400™; Neothylline™; Pulmozyme™ (Genentech Inc)Enzyme Replacement AgentsFor the treatment of cystic fibrosis.7656 (double strand)Drotrecogin alfaXigris™; Xigris™ (Eli Lilly & Co)Antisepsis AgentsFor treatment of severe sepsis267012EculizumabSoliris™; Soliris™ (Alexion Pharmaceuticals)For the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.188333EfalizumabRaptiva™; Raptiva™ (Genentech Inc)Immunomodulatory Agents; Immunosuppressive AgentsFo</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_US2023338282A1 |
| source | esp@cenet |
| subjects | BANDAGES, DRESSINGS OR ABSORBENT PADS DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF,TUBULAR STRUCTURES OF THE BODY, E.G. STENTS FILTERS IMPLANTABLE INTO BLOOD VESSELS FIRST-AID KITS FOMENTATION HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROSTHESES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS TREATMENT OR PROTECTION OF EYES OR EARS |
| title | POSTERIOR SEGMENT DRUG DELIVERY |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T12%3A07%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Alster,%20Yair&rft.date=2023-10-26&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS2023338282A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |